The DOI matches its Crossref record; 35 of the 37 references it cites were found in a registry or an index.
Rapid Tachyphylaxis of the Glucagon-Like Peptide 1–Induced Deceleration of Gastric Emptying in Humans
Open accessAbstract
OBJECTIVE: Glucagon-like peptide (GLP)-1 lowers postprandial glycemia primarily through inhibition of gastric emptying. We addressed whether the GLP-1–induced deceleration of gastric emptying is subject to rapid tachyphylaxis and if so, how this would alter postprandial glucose control. RESEARCH DESIGN AND METHODS: Nine healthy volunteers (25 ± 4 years old, BMI: 24.6 ± 4.7 kg/m2) were examined with intravenous infusion of GLP-1 (0.8 pmol · kg−1 . min−1) or placebo over 8.5 h. Two liquid mixed meals were administered at a 4-h interval. Gastric emptying was determined, and blood samples were drawn frequently. RESULTS: GLP-1 decelerated gastric emptying significantly more after the first meal compared with the second meal (P = 0.01). This was associated with reductions in pancreatic polypeptide levels (marker of vagal activation) after the first but not the second meal (P < 0.05). With GLP-1, glucose concentrations declined after the first meal but increased after the second meal (P < 0.05). The GLP-1–induced reductions in postprandial insulin and C-peptide levels were stronger during the first meal course (P < 0.05). Likewise, glucagon levels were lowered by GLP-1 after the first meal but increased after the second test meal (P < 0.05). CONCLUSIONS: The GLP-1–induced delay in gastric emptying is subject to rapid tachyphylaxis at the level of vagal nervous activation. As a consequence, postprandial glucose control by GLP-1 is attenuated after its chronic administration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Furthermore, GLP-1 can slow down gastric emptying by activating the vagus nerve, a part of the autonomic nervous system crucial for regulating the activities of the gastrointestinal tract.268”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [268]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GLP-1 can slow down gastric emptying through its effects on smooth muscles and the nervous system in the gastrointestinal tract.264,268”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [268]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Data also suggest that there is tachyphylaxis with prolonged use of GLP‐1 RAs [29, 60]”
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The magnitude of effect on GE, unlike the effects on glycaemic control or appetite, is attenuated with prolonged GLP-1 exposure.[2][3][4]”
From The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists (2020) · cites this paper as [3]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Native GIP mimicking postprandial GIP blood levels and GIPRAs did not reveal any relevant effects on GE. 3,[13][14][15]”
From The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists (2020) · cites this paper as [3]
Experimental — accuracy not yet measured
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Buse, J. B., Rosenstock, J., Sesti, G., Schmidt, W. E., Montanya, E., Brett, J. H., Zychma, M., & Blonde, L. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60659-0 · Cited by 1,503
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 1×
“Although the glucose-lowering effect of GLP-1 in the fasting state is primarily mediated by its glucose-dependent augmentation of insulin secretion and inhibition of glucagon release (4,5), the key mechanism driving the postprandial normalization of glycemia by GLP-1 is a marked deceleration of gastric emptying leadin…”
BackgroundSelf-citationGarber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057
Tissue and Plasma Concentrations of Amidated and Glycine-Extended Glucagon-Like Peptide I in Humans
Ørskov, C., Rabenhøj, L., Wettergren, A., Kofod, H., & Holst, J. J. (1994) · Diabetes · doi:10.2337/diab.43.4.535 · Cited by 919 · cited 1×
“determined in ethanol-extracted plasma as previously described (15,18), using antiserum 89 390 for the measurement of intact GLP-1 [7–36 amide] plus cleavage products.”
MethodSelf-citationNauck, M. A., Niedereichholz, U., Ettler, R., Holst, J. J., Ørskov, C., Ritzel, R., & Schmiegel, W. H. (1997) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1997.273.5.e981 · Cited by 817 · cited 2×
“fusion rate was based on previous studies (5,14) and was selected to increase”
BackgroundMethodSelf-citationTruncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670 · cited 1×
“A deceleration of gastric emptying by GLP-1 has been demonstrated in patients with type 2 diabetes and healthy individuals (5,8,14).”
BackgroundSelf-citationMitrakou, A., Kelley, D., Mokan, M., Veneman, T., Pangburn, T., Reilly, J., & Gerich, J. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201023260104 · Cited by 595 · cited 1×
“This is in contrast with previous studies showing a significant decline in glucagon levels after intravenous or oral glucose ingestion (31,32).”
ResultEnhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Nauck, M. A. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.4.912 · Cited by 506 · cited 3×
“Given the importance of GIP as a physiologic incretin hormone (15,34), this might theoretically impair postprandial insulin responses and thus worsen glucose control.”
BackgroundMethodSelf-citationWillms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502
Self-citation
Cited by
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170
“GLP-1 Actions in the Gastrointestinal Tract and Liver GLP-1R agonists inhibit gastric and small bowel motility, although the precise neuronal circuits responsible for these actions remain unclear, and the inhibition is subject to rapid tachyphylaxis and wanes with sustained GLP-1R activation (Nauck et al., 2011).”
BackgroundGlucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“In healthy human volunteers, intravenous GLP-1 decelerates gastric emptying after the first meal to a greater extent than after a second meal, indicating that GLP-1 inhibition of gastric emptying undergoes rapid desensitization [803].”
BackgroundSelf-citationGLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Self-citationGlucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“268 When activated, the vagus nerve can reduce the contraction of the stomach, thereby slowing down food emptying.”
BackgroundThe Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
Secher, A., Jelsing, J., Baquero, A. F., Hecksher-Sørensen, J., Cowley, M. A., Dalbøge, L. S., Hansen, G., Grove, K. L., Pyke, C., Raun, K., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci75276 · Cited by 961
“In 7 of 7 cells (from 5 mice), GLP-1(7-36)amide failed to change the current in the presence of bicuculline (Figure 2, D and F), demonstrating that GABA-A receptor activation was likely responsible for the inhibitory effects of GLP-1(7-36)amide on NPY neurons.”
InfluentialSteinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
Cardiovascular Biology of the Incretin System
Ussher, J. R., & Drucker, D. J. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1052 · Cited by 530
“Interpretation of studies demonstrating that acute GLP-1R activation lowers postprandial lipemia requires consideration of whether the findings are due in part to the acute effect of GLP-1R agonists to inhibit gastric emptying and gut motility, actions that are diminished with more sustained GLP-1R activation (93, 94).”
BackgroundGLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans
van Bloemendaal, L., IJzerman, R. G., ten Kulve, J. S., Barkhof, F., Konrad, R. J., Drent, M. L., Veltman, D. J., & Diamant, M. (2014) · Diabetes · doi:10.2337/db14-0849 · Cited by 427
“(48), whereas the weight-lowering effects persist over periods up to 3 years (49).”
BackgroundGraaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
“These studies reveal that even short-term continuous GLP-1R stimulation may be associated with some degree of rapid tachyphylaxis,most evident in effectsmediated through the vagus nerve and gastric emptying (Nauck et al., 2011).”
BackgroundFrías, J. P., Guja, C., Hardy, E., Ahmed, A., Dong, F., Öhman, P., & Jabbour, S. A. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30267-4 · Cited by 398
Nauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Self-citationBettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374
Self-citationRelationships Between Gastric Emptying, Postprandial Glycemia, and Incretin Hormones
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Diabetes Care · doi:10.2337/dc12-1609 · Cited by 335
“It was suggested that this tachyphylaxis occurs at the level of the vagus nerve (51).”
BackgroundEffects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
van Bloemendaal, L., ten Kulve, J. S., la Fleur, S. E., Ijzerman, R. G., & Diamant, M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0414 · Cited by 312
“Also in humans, the inhibitory effect of GLP-1 on gastric emptying is subject to tachyphylaxis (Nauck et al. 2011).”
Riddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J. (2013) · Diabetes Care · doi:10.2337/dc12-2454 · Cited by 288
“However, slowing of gastric emptying appears to be greater with short-acting than with longacting GLP-1RAs (13), possibly related to the observation that, with time, continuous exposure of GLP-1 leads to a reduction in its effect on gastric emptying (14).”
Gastric emptying and glycaemia in health and diabetes mellitus
Phillips, L. K., Deane, A. M., Jones, K. L., Rayner, C. K., & Horowitz, M. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2014.202 · Cited by 273
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
Nauck, M. A., & Meier, J. J. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0566 · Cited by 254
Self-citationAroda, V. R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13162 · Cited by 253
“In Europe, IDegLira is approved for treatment of type 2 diabetes inadequately controlled with oral glucose-lowering agents alone or in combination with a GLP-1 RA or basal insulin, and iGlarLixi is approved to improve glycemic control with metformin or metformin combined with another oral agent or with basal insulin.7…”
BackgroundInfluentialSeino, Y., & Yabe, D. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12065 · Cited by 247
Hjerpsted, J. B., Flint, A., Brooks, A., Axelsen, M. B., Kvist, T., & Blundell, J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13120 · Cited by 245
“However, some investigations indicate that this phenomenon is transient and the effect on gastric emptying diminishes over time.(49,50) The differing durations of action of GLP-1RAs seem to influence gastric emptying with continued dosing.”
BackgroundGlucagon-like peptide-1 receptors in the brain: controlling food intake and body weight
Baggio, L. L., & Drucker, D. J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci78371 · Cited by 245
“Furthermore, GLP-1R–dependent inhibition of gastric emptying is subject to rapid tachy-phylaxis (9, 10), and long-acting GLP-1R agonists or continuous administration of native GLP-1 produce weight loss independent of changes in gastric emptying (9).”
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Hammoud, R., & Drucker, D. J. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00783-3 · Cited by 244
“Notably, the actions of GLP1 to inhibit gastric emptying are subject to tachyphylaxis within a few hours of sustained GLP1R signalling 148 .”
Effects of GLP-1 and Its Analogs on Gastric Physiology in Diabetes Mellitus and Obesity
Maselli, D. B., & Camilleri, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_496 · Cited by 248
The expanding incretin universe: from basic biology to clinical translation
Drucker, D. J., & Holst, J. J. (2023) · Diabetologia · doi:10.1007/s00125-023-05906-7 · Cited by 243
Self-citationGlucagon‐like peptide‐1 receptor agonists in type 2 diabetes treatment: are they all the same?
Gentilella, R., Pechtner, V., Corcos, A., & Consoli, A. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3070 · Cited by 227
“Because these agents do not appear to have notable effects on gastric emptying, probably because of the rapid development of tachyphylaxis, this effect is mediated via enhanced postprandial insulin secretion and inhibited glucagon secretion.(10,128,132) Long‐acting GLP‐1 RAs also lower postprandial glucose excursions,…”
BackgroundHalawi, H., Khemani, D., Eckert, D., O'Neill, J., Kadouh, H., Grothe, K., Clark, M. M., Burton, D. D., Vella, A., Acosta, A., et al. (2017) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(17)30285-6 · Cited by 224
on behalf of the NN8022-1807 Investigators, Lean, M. E. J., Carraro, R., Finer, N., Hartvig, H., Lindegaard, M. L., Rössner, S., Van Gaal, L., & Astrup, A. (2014) · International Journal of Obesity · doi:10.1038/ijo.2013.149 · Cited by 210
Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver
Newsome, P. N., & Ambery, P. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.033 · Cited by 211
van Baar, M. J. B., van Ruiten, C. C., Muskiet, M. H. A., van Bloemendaal, L., IJzerman, R. G., & van Raalte, D. H. (2018) · Diabetes Care · doi:10.2337/dc18-0588 · Cited by 199
“The lack of efficacy of long-acting GLP-1RAs in reducing meal-related hyperglycemia might be explained by rapid tachyphylaxis of GLP-1RA–induced gastric emptying deceleration (33).”
BackgroundThe L-cell in nutritional sensing and the regulation of appetite
Spreckley, E. (2015) · Frontiers in Nutrition · doi:10.3389/fnut.2015.00023 · Cited by 198
“org and pancreatic secretion (14, 18, 74) and decreases the speed of intestinal transit, an effect, which may partly be due to the inhibited release of motilin by PYY, and a consequent decrease in intestinal migrating contractions (17, 75).”
BackgroundBeta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications
Wysham, C., & Shubrook, J. (2020) · Postgraduate Medicine · doi:10.1080/00325481.2020.1771047 · Cited by 193
Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence
Alicic, R. Z., Cox, E. J., Neumiller, J. J., & Tuttle, K. R. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00367-2 · Cited by 193
Kapitza, C., Forst, T., Coester, H. ‐., Poitiers, F., Ruus, P., & Hincelin‐Méry, A. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12076 · Cited by 191
“Interestingly, recent data indicate that the delay in gastric emptying by GLP-1 is reduced during continued exposure, probably due to tachyphylaxis [35].”
BackgroundAction and therapeutic potential of oxyntomodulin
Pocai, A. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.12.001 · Cited by 191
“[8] demonstrated in healthy volunteers that GLP-1-induced delay in gastric emptying is subject to rapid tachyphylaxis.”
BackgroundIncretin hormones and type 2 diabetes
Nauck, M. A., & Müller, T. D. (2023) · Diabetologia · doi:10.1007/s00125-023-05956-x · Cited by 190
Self-citationPlamboeck, A., Veedfald, S., Deacon, C. F., Hartmann, B., Wettergren, A., Svendsen, L. B., Meisner, S., Hovendal, C., Vilsbøll, T., Knop, F. K., et al. (2013) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00035.2013 · Cited by 183
“(45) showed that the effects of GLP-1 on gastric emptying as estimated by using a two-meal protocol shows rapid tachyphylaxis in humans, and, since there was also a marked reduction in PP levels (used as a marker for vagal activity) after the first but not the second meal, they suggested that the tachyphylaxis happene…”
Self-citationJones, A. G., McDonald, T. J., Shields, B. M., Hill, A. V., Hyde, C. J., Knight, B. A., & Hattersley, A. T. (2016) · Diabetes Care · doi:10.2337/dc15-0258 · Cited by 178
Battle of GLP-1 delivery technologies
Yu, M., Benjamin, M. M., Srinivasan, S., Morin, E. E., Shishatskaya, E. I., Schwendeman, S. P., & Schwendeman, A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.009 · Cited by 180
Bossart, M., Wagner, M., Elvert, R., Evers, A., Hübschle, T., Kloeckener, T., Lorenz, K., Moessinger, C., Eriksson, O., Velikyan, I., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2021.12.005 · Cited by 179
Umapathysivam, M. M., Lee, M. Y., Jones, K. L., Annink, C. E., Cousins, C. E., Trahair, L. G., Rayner, C. K., Chapman, M. J., Nauck, M. A., Horowitz, M., et al. (2014) · Diabetes · doi:10.2337/db13-0893 · Cited by 193
“8 pmol/kg/min, which is known to result in receptor stimulation representative of pharmacological agents (11).”
BackgroundMethodResultInfluentialSelf-citationLiraglutide: short‐lived effect on gastric emptying—long lasting effects on body weight
Jelsing, J., Vrang, N., Hansen, G., Raun, K., Tang‐Christensen, M., & Bjerre Knudsen, L. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01557.x · Cited by 155
“[22] proposed that because of the short timeframe the gastric inhibitory effects of GLP-1 were subject to tachyphylaxis rather than to desensitization which usually depends on receptor internalization and degradation.”
BackgroundResultInfluentialEmerging combinatorial hormone therapies for the treatment of obesity and T2DM
Sadry, S. A., & Drucker, D. J. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.47 · Cited by 174
Glucagon-Like Peptide-1: Glucose Homeostasis and Beyond
Cho, Y. M., Fujita, Y., & Kieffer, T. J. (2014) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170315 · Cited by 174
“Interestingly, continuous intravenous GLP-1 infusion in humans causes a rapid decrease in the gastric emptying effect of GLP-1 (108).”
BackgroundAhrén, B., Leguizamo Dimas, A., Miossec, P., Saubadu, S., & Aronson, R. (2013) · Diabetes Care · doi:10.2337/dc12-2006 · Cited by 172
Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?
Binder, S. (2012) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2011-301236 · Cited by 169
Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide
Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae719 · Cited by 157
“Nauck et al evaluated the effect of exogenous IV GLP-1 (7-36 amide), delivered at 0.8 pmol.kg − 1. l − 1 for 8 hours, on gastric emptying (by a dye dilution technique) of 2 successive meals consumed at baseline and after 4 hours of GLP-1 exposure (19).”
InfluentialSelf-citationCornell, S. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13230 · Cited by 156
Gulak, M. A., & Murphy, P. (2023) · Canadian Journal of Anesthesia/Journal canadien d'anesthésie · doi:10.1007/s12630-023-02521-3 · Cited by 153
van Bloemendaal, L., Veltman, D. J., ten Kulve, J. S., Groot, P. F. C., Ruhé, H. G., Barkhof, F., Sloan, J. H., Diamant, M., & Ijzerman, R. G. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12506 · Cited by 151
“Weight loss during GLP-1 receptor agonist treatment is also observed in the absence of nausea [40,41] and the effects on gastric emptying are subject to rapid desensitization [42], while the effects on body weight persist over periods up to 3 years [43].”
BackgroundLorenz, M., Pfeiffer, C., Steinstraesser, A., Becker, R. H. A., Rütten, H., Ruus, P., & Horowitz, M. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.04.001 · Cited by 161
Kobori, T., Onishi, Y., Yoshida, Y., Tahara, T., Kikuchi, T., Kubota, T., Iwamoto, M., Sawada, T., Kobayashi, R., Fujiwara, H., et al. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14005 · Cited by 144
Do GLP-1–Based Therapies Increase Cancer Risk?
Nauck, M. A., & Friedrich, N. (2013) · Diabetes Care · doi:10.2337/dcs13-2004 · Cited by 145
Self-citationAn adaptationist perspective on the etiology of depression
Durisko, Z., Mulsant, B. H., & Andrews, P. W. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.09.032 · Cited by 140
“This kind of response has been well documented in other areas of medicine (e. g., Eghøj and Sørensen, 2012; Nauck et al., 2011; Samaha et al., 2007).”
BackgroundThe role of glucagon‐like peptide‐1 impairment in obesity and potential therapeutic implications
Madsbad, S. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12119 · Cited by 146
“In the same study, islet hormone responses to GLP-1 were not markedly reduced by chronic GLP-1 infusion, and the authors concluded that tachyphylaxis of the gastric emptying effect of GLP-1 is probably not a result of downregulation or desensitization of the GLP-1 receptor, but rather inhibition of the vagal nerve [64…”
BackgroundHermansen, K., Bækdal, T. A., Düring, M., Pietraszek, A., Mortensen, L. S., Jørgensen, H., & Flint, A. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12133 · Cited by 143
“Tachyphylaxis of gastric emptying has also been reported with native GLP-1 in humans [35].”
BackgroundUrva, S., Coskun, T., Loghin, C., Cui, X., Beebe, E., O'Farrell, L., Briere, D. A., Benson, C., Nauck, M. A., & Haupt, A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14110 · Cited by 143
“Sustained exposure to GLP-1RA (via tirzepatide or using selective GLP-1RA, semaglutide) resulted in tachyphylaxis of the GE effect in mice, as demonstrated in previous studies.(3,4)”
Self-citationGlucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents
Gallwitz, B. (2011) · Drugs · doi:10.2165/11592810-000000000-00000 · Cited by 142
“This hypothesis is supported by recent findings that the GLP-1-induced delay in gastric emptying is subject to rapid tachyphylaxis at the level of vagal nervous activation.([95]) Effects on surrogate parameters for b-cell function as well as adverse events were comparable to the effects of other GLP-1 receptor agonist…”
El‐Boghdadly, K., Dhesi, J., Fabb, P., Levy, N., Lobo, D. N., McKechnie, A., Mustafa, O., Newland‐Jones, P., Patel, A., Pournaras, D. J., et al. (2025) · Anaesthesia · doi:10.1111/anae.16541 · Cited by 147
Abd El Aziz, M. S., Kahle, M., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12804 · Cited by 155
“Glycaemic control was better with (particularly long-acting) GLP-1 RAs, although fasting plasma glucose was better controlled by insulin (Figure 2), especially in comparison to short-acting GLP-1 RAs.”
BackgroundInfluentialSelf-citationMaselli, D., Atieh, J., Clark, M. M., Eckert, D., Taylor, A., Carlson, P., Burton, D. D., Busciglio, I., Harmsen, W. S., Vella, A., et al. (2022) · Obesity · doi:10.1002/oby.23481 · Cited by 136
“This is consistent with tachyphylaxis in the effect on GES as previously described with GLP-1 [33].”
van Zuylen, M. L., Siegelaar, S. E., Plummer, M. P., Deane, A. M., Hermanides, J., & Hulst, A. H. (2024) · British Journal of Anaesthesia · doi:10.1016/j.bja.2024.01.001 · Cited by 132
Unraveling oxyntomodulin, GLP1's enigmatic brother
Pocai, A. (2012) · Journal of Endocrinology · doi:10.1530/joe-12-0368 · Cited by 133
Parker, V. E. R., Robertson, D., Wang, T., Hornigold, D. C., Petrone, M., Cooper, A. T., Posch, M. G., Heise, T., Plum-Moerschel, L., Schlichthaar, H., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz047 · Cited by 123
“It is established that GLP-1 promotes a delay in GET via transmission of cholinergic and peptidergic inhibitory signals to the vagus nerve and tachyphylaxis is thought to arise through adaptation of the parasympathetic nervous system (11,29).”
BackgroundSelf-citationPhillips, L. K., & Prins, J. B. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06491.x · Cited by 132
Iepsen, E. W., Lundgren, J., Dirksen, C., Jensen, J.-E., Pedersen, O., Hansen, T., Madsbad, S., Holst, J. J., & Torekov, S. S. (2015) · International Journal of Obesity · doi:10.1038/ijo.2014.177 · Cited by 118
Self-citationGLP‐1 based therapies: differential effects on fasting and postprandial glucose
Fineman, M., Cirincione, B., Maggs, D., & Diamant, M. (2012) · Diabetes, obesity and metabolism · doi:10.1111/j.1463-1326.2012.01560.x · Cited by 123
“that demonstrated a reduced gastric emptying and PPG effect at the lunch meal compared to the breakfast meal during a continuous intravenous infusion of native GLP-1 [77].”
BackgroundMechanisms, physiology, and recent research progress of gastric emptying
Liu, W., Jin, Y., Wilde, P. J., Hou, Y., Wang, Y., & Han, J. (2020) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2020.1784841 · Cited by 122
Behary, P., Tharakan, G., Αλεξιάδου, Κ., Johnson, N. A., Albrechtsen, N. J. W., Kenkre, J. S., Cuenco, J., Hope, D. C. D., Anyiam, O., Choudhury, S., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0449 · Cited by 120
“GLP-1, OXM, and PYY are released from the L cells of the small intestine and colon, and their postprandial secretion is augmented several-fold after RYGB (4,5).”
MethodInfluentialSelf-citationDo we know the true mechanism of action of the DPP ‐4 inhibitors?
Andersen, E. S., Deacon, C. F., & Holst, J. J. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13018 · Cited by 129
Self-citationReview article: a comparison of glucagon‐like peptides 1 and 2
Janssen, P., Rotondò, A., Mulè, F., & Tack, J. F. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12092 · Cited by 130
“76 It circulates in two equally potent forms, GLP-1(7-36 amide) and GLP-1(7-37), although the amidated form is more abundant after eating.”
BackgroundInfluentialDenison, H., Nilsson, C., Löfgren, L., Himmelmann, A., Mårtensson, G., Knutsson, M., AL‐Shurbaji, A., Tornqvist, H., & Eriksson, J. W. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12221 · Cited by 104
“This time-dependent effect would be in line with human data indicating that tachyphylaxis of the GLP-1-induced delay in gastric emptying may develop rapidly in healthy individuals [33].”
ResultMechanisms for the Antihyperglycemic Effect of Sitagliptin in Patients with Type 2 Diabetes
Muscelli, E., Casolaro, A., Gastaldelli, A., Mari, A., Seghieri, G., Astiarraga, B., Chen, Y., Alba, M., Holst, J. J., & Ferrannini, E. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1205 · Cited by 111
“DPP-4 inhibitors are known not to slow down gastric emptying to any meaningful extent (10, 27), and even the inhibitory effect of GLP-1 on gastric motility is subject to tachyphylaxis (28).”
BackgroundSelf-citationTargeting the incretin system in obesity and type 2 diabetes mellitus
Ansari, S., Khoo, B. C. E., & Tan, T. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-024-00979-9 · Cited by 127
“However, countering this hypothesis, it is known that the inhibitory effect of GLP1 on gastric emptying is subject to rapid tachyphy-laxis within a few hours 61 , whereas the weight-lowering effect of GLP1RA treatment persists for years 63 .”
The therapeutic potential of GLP‐1 receptor biased agonism
Jones, B. J. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15497 · Cited by 107
“The effect of GLP-1 on gastric emptying undergoes rapid tachyphylaxis (Nauck et al., 2011) and this observation has been used to support the use of “short-acting” GLP-1 agonists that allow a between-dose re-sensitisation period and restora- tion of the beneficial effects of gastric emptying on…”
MethodHiramoto, B. A., McCarty, T. R., Lodhia, N. A., Jenkins, A., Elnaiem, A. D., Muftah, M., Flanagan, R. F., & Chan, W. W. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002820 · Cited by 120
Glucagon-like peptides 1 and 2 in health and disease: A review
Marathe, C. S., Rayner, C. K., Jones, K. L., & Horowitz, M. (2013) · Peptides · doi:10.1016/j.peptides.2013.01.014 · Cited by 100
Min, J. S., Jo, S. J., Lee, S., Kim, D. Y., Kim, D. H., Lee, C. B., & Bae, S. K. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s506957 · Cited by 131
“113 Therefore, findings from real-world evidence studies evaluating the long-term safety of GLP-1 RAs and a dual GLP-1/GIP RA should be carefully considered.”
Calvarysky, B., Dotan, I., Shepshelovich, D., Leader, A., & Cohen, T. D. (2024) · Drug Safety · doi:10.1007/s40264-023-01392-3 · Cited by 97
“An open question remains whether chronic use of GLP1RAs will result in tachyphylaxis of the gastric slowing effect, which will mitigate the risk of DDI [51–53].”
BackgroundAulinger, B. A., Bedorf, A., Kutscherauer, G., de Heer, J., Holst, J. J., Göke, B., & Schirra, J. R. J. (2013) · Diabetes · doi:10.2337/db13-1455 · Cited by 98
“The only study addressing this issue used pharmacological doses of GLP-1 and demonstrated that in the short-term, GE was further inhibited by GLP-1 (50).”
BackgroundSelf-citationHuthmacher, J. A., Meier, J. J., & Nauck, M. A. (2020) · Diabetes Care · doi:10.2337/dc20-0498 · Cited by 91
Self-citationNewer GLP-1 receptor agonists and obesity-diabetes
Brown, E. E., Cuthbertson, D. J., & Wilding, J. P. H. (2018) · Peptides · doi:10.1016/j.peptides.2017.12.009 · Cited by 110
Pathophysiology and pharmacotherapy of gastroparesis: current and future perspectives
Stevens, J. E., Jones, K. L., Rayner, C. K., & Horowitz, M. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.795948 · Cited by 92
“The latter may also improve postprandial glycaemia by stimulating the release of GLP-1 and other small intestinal hormones [59].”
BackgroundInfluentialChao, A. M., Wadden, T. A., Walsh, O. A., Gruber, K. A., Alamuddin, N., Berkowitz, R. I., & Tronieri, J. S. (2019) · Obesity · doi:10.1002/oby.22653 · Cited by 84
“Studies have also suggested that the effects of long-acting GLP-1 agonists on gastric emptying may diminish over time because of tolerance and tachyphylaxis (20,21), which may have resulted in diminished perceptions of appetite control after 24 weeks of treatment.”
BackgroundPabreja, K., Mohd, M. A., Koole, C., Wootten, D. L., & Furness, S. G. B. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12313 · Cited by 99
“, 2008); however, this effect is subject to tachyphylaxis (Nauck et al., 2011) and as a result, long-acting GLP-1 analogues are less efficacious in controlling postprandial glucose excursion (Degn et al.”
BackgroundRelationship Between Control of Glycemia and Gastric Emptying Disturbances in Diabetes Mellitus
Halland, M., & Bharucha, A. E. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.11.021 · Cited by 90
Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies
Gerich, J. E. (2013) · International Journal of General Medicine · doi:10.2147/ijgm.s51665 · Cited by 95
“The gastric emptying effect of GLP-1, which lowers PPG, has been shown to decrease after chronic administration (tachyphylaxis) of intravenous GLP-1 in healthy human subjects.(101) An area that remains to be investigated is whether tachyphylaxis occurs with GLP-1 analogs and if the longterm efficacy in reducing PPG va…”
BackgroundOwens, D., Monnier, L., & Bolli, G. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.09.004 · Cited by 82
Jones, K. L., Huynh, L. Q., Hatzinikolas, S., Rigda, R. S., Phillips, L. K., Pham, H. T., Marathe, C. S., Wu, T., Malbert, C., Stevens, J. E., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13956 · Cited by 83
“hence, have a dominant postprandial effect, while long-acting GLP-1RAs may have minimal or no effect on gastric emptying with sustained administration as a result of tachyphylaxis, so that their glucose-lowering is preferentially preprandial, reflecting stimulation of insulin and suppression of glucagon.(21,24) This c…”
BackgroundActions of glucagon‐like peptide‐1 receptor ligands in the gut
Holst, J. J., Andersen, D. B., & Grunddal, K. V. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15611 · Cited by 87
Self-citationSmits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Cahen, D. L., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12593 · Cited by 74
“These findings are likely explained by chronic stimulation of the GLP-1 receptor and its subsequent desensitization (tachyphylaxis) during treatment with long-acting GLP-1 receptor agonists [89].”
BackgroundResultTronieri, J. S., Wadden, T. A., Walsh, O., Berkowitz, R. I., Alamuddin, N., Gruber, K., Leonard, S., Bakizada, Z. M., & Chao, A. M. (2020) · International Journal of Obesity · doi:10.1038/s41366-019-0348-6 · Cited by 74
How glucagon-like peptide 1 receptor agonists work
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Endocrine Connections · doi:10.1530/ec-21-0130 · Cited by 71
“The figure illustrates GLP-1(7-36) amide.”
Adetunji, O., Kalra, S., Baruah, M., Sahay, R. K., Unnikrishnan, A., & Uppal, S. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.176351 · Cited by 82
“While this may mean less gastrointestinal side effects, it also reflects in the better PPG efficacy of short‐acting molecules.[11,12,78] However, this may not always hold true.”
BackgroundVetter, M. L., Wadden, T. A., Teff, K. L., Khan, Z. F., Carvajal, R., Ritter, S., Moore, R. H., Chittams, J. L., Iagnocco, A., Murayama, K. M., et al. (2014) · Diabetes · doi:10.2337/db14-0558 · Cited by 76
“Tolerance to GLP-1 as a result of tachyphylaxis or downregulation of the GLP1R may also have developed after RYGB, which may have further attenuated improvements in glycemia (45).”
BackgroundHulst, A. H., Polderman, J. A. W., Siegelaar, S. E., van Raalte, D. H., DeVries, J. H., Preckel, B., & Hermanides, J. (2020) · British Journal of Anaesthesia · doi:10.1016/j.bja.2020.10.023 · Cited by 74
Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
Michałowska, J., Miller‐Kasprzak, E., & Bogdański, P. (2021) · Nutrients · doi:10.3390/nu13020351 · Cited by 83
“showed that GLP-1–induced delay in gastric emptying is subject to rapid tachyphylaxis as an intravenous administration of GLP-1 in healthy subjects inhibited gastric emptying to a greater extent after the first meal than after the second meal [100].”
Background
Metadata
- Authors
- Nauck, M. A., Kemmeries, G., Holst, J. J., & Meier, J. J.
- Affiliations
- Diabeteszentrum Bad Lauterberg (DE)
- Conservative Emergency Room, Klinikum Krefeld, Krefeld, Germany
- University of Copenhagen (DK)
- St. Josef-Hospital (DE)
- Corresponding author
- Nauck, Michael A.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2011-04-23
- Volume
- 60
- Issue
- 5
- Pages
- 1561-1565
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC3292331
- OpenAlex
- W2163229244
- Cited by
- 392
- References
- 37
- Citations by year
- 2026: 35 · 2025: 32 · 2024: 38 · 2023: 23 · 2022: 18 · 2021: 22 · 2020: 21 · 2019: 23 · 2018: 20 · 2017: 17 · 2016: 24 · 2015: 26 · 2014: 33 · 2013: 42 · 2012: 11
- FWCI
- 24.10
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- glucagon-like peptide-1, tachyphylaxis, gastric emptying, postprandial glucose control, vagal activation, pancreatic polypeptide, insulin secretion, glucagon, C-peptide, mixed meal
- MeSH terms
- Adult, Blood Glucose, C-Peptide, Gastric Emptying, Glucagon, Humans, Male, Tachyphylaxis, Postprandial Period, Glucagon-Like Peptide 1, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.